解晓雯博士，北京大学药学院化学生物学系研究员，博士生导师，北京大学博雅青年学者，天然药物及仿生药物全国重点实验室研究员，国家高层次海外人才。解晓雯博士本科毕业于吉林大学生物与农业工程学院，博士毕业于北京大学前沿交叉学科研究院，随后分别在美国德州西南医学中心和华盛顿大学进行博士后训练，于2025年10月正式入职北京大学药学院。Dr. Xiaowen Xie is a Principal Investigator and doctoral supervisor in the Department of Chemical Biology, School of Pharmaceutical Sciences, Peking University. She is also a Peking University Boya Young Scholar, a researcher at the State Key Laboratory of Natural and Biomimetic Drugs, and a recipient of China’s National High-level Overseas Talent Program. Dr. Xie received her bachelor’s degree from the College of Biological and Agricultural Engineering, Jilin University, and her Ph.D. from the Academy for Advanced Interdisciplinary Studies, Peking University. She subsequently completed postdoctoral training at UT Southwestern Medical Center and the University of Washington. In October 2025, she officially joined the School of Pharmaceutical Sciences, Peking University.
本课题组致力于利用蛋白组学分析、降解组学分析、深度突变扫描、Cryo-EM等多学科交叉技术，专注于药物靶点发现和药物设计的基础研究。尤其关注E3连接酶识别底物的作用模式、分子胶介导的「难成药靶点」蛋白水平调控的作用机制，及全新分子胶的发现研究。在拓展分子胶可靶向的E3连接酶靶向空间、揭示新型分子胶作用模式等方面取得系列成果。总计发表SCI论文9篇，其中近5年以第一作者（含共同）及通讯作者，发表高水平论文3篇，包括Nature 论文2篇等。研究成果被同期 Nature、Nature Reviews Drug Discovery、Molecular Cell、Cancer Discovery等杂志专题报道及评述。The group integrates proteomics, degradomics, deep mutational scanning, Cryo-EM, and other interdisciplinary approaches to study drug target discovery and mechanism-driven drug design. We focus on how E3 ligases recognize substrates, how molecular glues regulate traditionally difficult-to-drug targets at the protein level, and the discovery of new molecular glues. The group has made a series of advances in expanding the E3 ligase target space accessible to molecular glues and revealing new modes of molecular glue action. Dr. Xie has published 9 SCI-indexed papers, including 3 high-impact papers in the past five years as first author (including co-first author) and corresponding author, with 2 papers in Nature. These studies have been highlighted or reviewed by Nature, Nature Reviews Drug Discovery, Molecular Cell, Cancer Discovery, and other journals.
